
Key Biden agency dropped $60K on overseas conference with DEI workshop: 'Should never happen'
FIRST ON FOX: A government watchdog has uncovered that former President Joe Biden's Food and Drug Administration (FDA) spent tens of thousands of taxpayer dollars sending top officials to a conference in Scotland that included diversity, equity and inclusion (DEI) workshops.
The Functional Government Initiative (FGI), via a FOIA request, discovered that the Biden FDA spent an estimated $60,000 on a dozen staffers, including Senior Advisor for Health Equity Dr. Charlene Le Fauve, to attend the Society for Research on Nicotine and Tobacco's (SRNT's) conference in Edinburgh, Scotland, in March 2024.
While at the conference, members of the team attended a workshop that focused on the "stigma" facing LGBTQ+ people in the field of tobacco research.
Topics included in that workshop, according to the FDA's own report on the trip, included "how anti-LGBTQ+ legislation and discriminatory and stigmatizing environments toward LGBTQ+ populations impact tobacco use and tobacco control research" and "process to develop a community-based participatory research project to address smoking cessation among transgender individuals in Argentina."
Another topic discussed was "the challenges of conducting research on tobacco use in the high-stigma environment of pregnancy in a post-Dobbs era."
Le Fauve justified the trip, in part, by claiming "the knowledge gained at the meeting is critical to attendees' ability to understand emerging scientific issues that may impact their work and their ability to effectively move forward agency initiatives."
"The formal SRNT conference included many sessions where health equity was an identified focus and I attended several which were highly relevant, well done, and informative including the Presidential Symposium that included three presenters supporting the premise that in order to have a global impact on the tobacco smoking pandemic, nicotine and tobacco research must broaden its vision beyond wealthy countries to include research and researchers in low and middle-income countries (LMICs), where the vast majority of the world's people who smoke live," Le Fauve added.
Also present on the trip was Center for Tobacco Products Director Brian King, who was recently relieved of his duty by the Trump administration in a move that a former agency official told Fox News Digital was a result of the FDA straying from its core mission under the Biden administration and focusing on issues like DEI.
"There were many, many failures in the key core missions for the center that needed dramatic change in new leadership," David Oliveira, who recently left the FDA after six years, told Fox News Digital last month, explaining that the FDA was ceding responsibility to other departments and not doing enough to crackdown on China flooding the market with illicit vapes.
FGI Communications Director Roderick Law told Fox News Digital in a statement that spending tens of thousands of dollars to send a dozen employees to a conference in Scotland is another example of the agency losing focus on its mission.
"I, like anyone else in the world, would love to have a $60,000 vacation paid for by my employer," Law said.
"Sadly, this dream became reality for 12 people on the taxpayer's back. How can a group of government officials spend $60,000 on an LGBTQ+ workshop? How is it possible that this trip helped the agency stop illegal Chinese-made products or process applications for new products that could provide for harm reduction? This kind of waste should never happen again."
Fox News Digital reached out to the FDA for comment.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
34 minutes ago
- Associated Press
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chief Financial Officer (CFO) and interim CEO, will continue serving as CFO and as a member of the Board of Directors. 'We are very pleased to welcome Bob to the executive leadership team as we continue to execute on our path forward. Bob's experience, track record and deep understanding of the biopharmaceutical industry will be invaluable as we scale as a commercial entity. With our launch in Europe underway and potential U.S. Food and Drug Administration (FDA) approval in the coming months, we believe this appointment is timely and positions us to drive value for our stakeholders,' commented Faisal G. Sukhtian, Chairman of the Outlook Therapeutics Board of Directors. Mr. Jahr brings more than 20 years of experience in the biopharmaceutical industry building and leading commercial teams spanning therapeutic areas including rare disease, oncology, hematology, autoimmunology, neuroscience, cardiovascular and inflammation. Over the course of his career, he has led operational and commercial efforts for multiple billion dollar assets and franchises. 'LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) has the potential to truly transform the global retina market and offer a much-needed ophthalmic formulation of bevacizumab for wet AMD,' added Mr. Jahr. 'With the commercial launch underway in Europe and potential FDA approval in the U.S. in the near term, I am excited to join the team at such a pivotal time for Outlook Therapeutics. I look forward to adding the depth and breadth of my experience to Outlook Therapeutics and continue building momentum to position it as a leader in the ophthalmology market.' Mr. Jahr joins Outlook Therapeutics having most recently served as the Chief Commercial Officer for Sobi North America (NA), where he oversaw commercial strategy, planning and execution excellence, which includes accountability for all marketing, sales, operations and market access activities. During his tenure at Sobi NA, Mr. Jahr led the immunology and hematology franchises, and three global development asset teams focused on preparing for regulatory submission, life cycle management and launch. Prior to his role at Sobi NA he served as General Manager & Vice President Head of International Markets at UCB Pharma SA (UCB) where he managed the company's portfolio in markets including China, Japan, Brazil, AUS, Canada, Middle East and Latin America. He also served as VP Head of US Payer Value, Pricing, Strategy & Innovation at UCB where he was responsible for developing teams during a period of expansion and launches. Prior to UCB he held leadership roles in sales, marketing, operations, payor strategy, and market access at Amgen. Mr. Jahr holds a Master of Business Administration degree and a Bachelor of Science degree in Business Administration and Management from University of Montana. Inducement Grant Additionally, Outlook Therapeutics announced that the independent members of its Board of Directors approved the issuance of an option to purchase 800,000 shares of common stock to Mr. Jahr in accordance with Nasdaq Listing Rule 5635(c)(4), as a material inducement to Mr. Jahr's start of employment with Outlook Therapeutics. The option will be issued on July 1, 2025 with an exercise price per share equivalent to the closing price of Outlook Therapeutics' common stock on the date of grant. The option will vest over four years, with 25% of the shares subject to the option vesting on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the three years thereafter, subject to Mr. Jahr's continuous service through the applicable vesting date. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'continue,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' or 'would' the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, expectations concerning the therapeutic potential of ONS-5010/LYTENAVA™ as a treatment of wet AMD, Outlook Therapeutics' commercialization strategy, the market opportunity for ONS-5010/LYTENAVA™, expectations concerning decisions of regulatory bodies and the timing thereof, ONS-5010/LYTENAVA™'s potential as the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal indications, including wet AMD, in the United States and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, the sufficiency of Outlook Therapeutics' resources, unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including the long-term impacts of ongoing overseas conflicts, tariffs and trade tensions, fluctuations in inflation and interest rates and other economic uncertainty), as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, the Quarterly Report on Form 10-Q for fiscal quarter ended March 31, 2025 and future quarterly reports Outlook Therapeutics files with the SEC. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. Investor Inquiries: Jenene Thomas Chief Executive Officer JTC Team, LLC T: 908.824.0775 [email protected]


Fox News
41 minutes ago
- Fox News
Socialist mayoral candidate Zohran Mamdani under fire for plan to tax 'richer and whiter neighborhoods'
Socialist Zohran Mamdani, the presumptive Democratic nominee for New York City mayor, is facing criticism over a campaign policy document that explicitly calls for shifting the city's tax burden onto "richer and whiter neighborhoods." Mamdani caused a political earthquake in this week's primary, trouncing former New York Gov. Andrew Cuomo in a stunning upset, all but securing his place on the November ballot. Housing affordability has been a central pillar of his campaign. A policy document titled "Stop the Squeeze on NYC Homeowners" from Mamdani's mayoral campaign website argues that the city's current property tax system disproportionately benefits wealthy, White homeowners, particularly in Manhattan and affluent areas of Brooklyn, by allowing them to pay far less in taxes due to outdated assessment caps. In contrast, Black, Latino and immigrant homeowners in neighborhoods like Brownsville and Jamaica in the outer borough of Queens are overburdened and at higher risk of foreclosure. His solution? "Shift the tax burden from overtaxed homeowners in the outer boroughs to more expensive homes in richer and whiter neighborhoods," the proposal reads. "The property tax system is unbalanced because assessment levels are artificially capped, so homeowners in expensive neighborhoods pay less than their fair share." The proposal would reduce the taxable portion of assessed property values citywide, and offset that by raising actual tax rates in wealthier areas. The result: lower tax bills for lower-income neighborhoods and higher ones for affluent areas — which the campaign describes as "richer and whiter." The racial component of the policy position has come in for criticism online, with broadcaster Mark Levin sharing a New York Post story about the proposal and writing "Oh, and Mamdani is racist, too." Political commentator Eric Daugherty also brandished it as explicitly "racist" on X, while the New York Post editorial board also slammed the proposal as "pure racism." Fox News Digital reached out to Mamdani's campaign for comment but did not immediately receive a response. The campaign document also highlights racial disparities in deed theft and "tangled titles," which are situations where someone lives in a home they believe they own — often through inheritance — but their name is not on the deed, creating legal uncertainty about ownership. The document states that predominantly Black neighborhoods face these challenges at much higher rates than White neighborhoods. To address this, Mamdani is proposing a $10 million "Tangled Title Fund" to help city residents hire lawyers and clear legal titles so they can secure full homeownership rights and benefits. Mamdani is a member of the Democratic Socialists of America, whose preamble discusses a way to "end white supremacy and racial oppression because its destruction is in the interest of all workers, including white workers." Overall, the housing document frames the city's housing inequities as structurally racist and economically unjust. The document also claims that the city's tax lien sale system is exploitative and racist. When a homeowner falls behind on property taxes under the system, the city sells that debt to a private trust of Wall Street-backed investors, usually at a discount. instead of collecting the debt directly. "The tax lien sale has been particularly harmful to Black, brown, and working-class homeowners, leading many homeowners to lose their home to foreclosure, or forcing them to sell below market value in order to pay off their accumulating debts," the document reads. "The city is six times more likely to sell a tax lien in a Black neighborhood than a white neighborhood. This policy is extracting wealth from Black, brown, and working-class communities and stripping New Yorkers of their homes." Mamdani said he will end the system on his first day in office and create a new tax collection system that provides "additional opportunities" for homeowners to enter into payment plans, pay down their debt and stay in their homes. The Queens assemblyman wants to build 200,000 new publicly-subsidized affordable homes and immediately freeze rents for the city's 2.4 million stabilized tenants. His proposals call for multi-year rent freezes and massive investment in public housing. Critics argue his proposals could worsen existing problems in the rental market,


Fox News
an hour ago
- Fox News
DAN GAINOR: The good, the bad, and the absurd: June's wildest political moments and celebrity meltdowns
June was a wild month. We had the good June – June Lockhart of "Lassie" and "Petticoat Junction" turning 100 (Salute!). Then, there was the bad June – riots in LA, military action in Iran and a socialist winning the Democratic mayoral primary in New York, New York (no longer my kind of town). The "mostly peaceful" riots featured the now-famous quote about "people having fun watching cars burn." And the action in Iran had its own special moments discussed below. Thankfully, it all ended peacefully, unless you live in NYC. With the month concluding on a hot note weatherwise, just before July arrived. 1. With friends like these: CNN's "OutFront" host Erin Burnett was out in left field about her time in Iran. The mullahs who run Iran have caused the deaths of hundreds of Americans, including over 600 U.S. servicemen killed by Iranian-backed militias in Iraq. Burnett still scored with the second stupidest quote of the month: "I remember at one point being in Tehran years ago, and they're chanting 'Death to America' all around me, even as I say, 'Oh, I'm an American, reporting for CNN.' And they were happy to speak to me. So those two sort of jarring realities of the chant and yet, the friendliness, have existed together." Somehow, that doesn't sound all that "friendly" to most Americans. 2. Democrat no more: Former Biden White House press secretary Karine Jean-Pierre declared she wasn't a Democrat anymore. Based on her many lies and misstatements at the White House, perhaps, KJP is going to create a modern version of the No Nothing Party. Her comments were in pursuit of publicity for her upcoming book, "Independent: A Look Inside a Broken White House, Outside the Party Lines." Her decision to become "independent" was bashed by both left and right. Maybe the big bipartisan moment in America right now is making fun of former Biden staffers. 3. Go West?: Former seventh-tier presidential candidate and general gadfly Cornel West still shows up in television segments on CNN – this June on "CNN NewsNight with Abby Phillip." That's the same network that called him, "the eccentric professor," when he resigned from Harvard over a tenure dispute. He took his eccentricity to CNN to blast the United States for using nuclear weapons on Japan in World War II, even though that ended the war. But how he did it was … special. West complained that it was "not a high moral moment" for "those of us to go all the way back to the United States to kill 250 million people in two days in Hiroshima and Nagasaki." No one corrected him, they just moved on. The look from conservative contributor Scott Jennings that followed was priceless. (For the record, the word the professor wanted was, "thousand" not "million." Oops.) 4. On the run: Maybe I love this story because it's almost local. A pet zebra escaped and went on runabout (the Australian walkabout but faster) in Tennessee, dominating the news for over a week because he wasn't easy to catch and, zebras are cute. "Ed" the Zebra broke free and ran down I-24 at one point, causing the road to be closed. Even then, he slipped away, eventually being rounded up and helicoptered back home in a net, taking in the sights above the beautiful mountains of the Volunteer state. Ed might have been chasing his glory like the zebra in the movie, "Racing Stripes." (That cast shockingly included Hayden Panettiere and voices of Jeff Foxworthy, Steve Harvey and Snoop Dog. Everybody has a mortgage to pay.) 5. Alternative media: Billionaire Mark Cuban criticized life in the liberal social media Fortress of Solitude, saying it isn't all it's cracked up to be. Cuban said Bluesky, which was created to be a lefty alternative to Twitter/X, is toxic and "hateful." He used the platform to criticize … the platform: "Even if you agree with 95% of what a person is saying on a topic, if there is one point that you might call out as being more of a gray area, they will call you a fascist etc." This isn't especially a surprise to conservatives who saw how the left managed every other platform from Twitter to YouTube, censoring content like it was the old Soviet Union or the Biden White House. Cuban also made news this month claiming the Kamala Harris campaign considered him as a possible vice president. The "Shark Tank" star wisely admitted one reason he declined was, "I'm not very good as the No. 2 person." Like him or not, he would outshine Harris on his worst day. You don't get to be a shark by being easygoing. 6. Millionaires vs. billionaires: Every month, it's just a question of which Hollywood actor/actress will say the stupidest thing. It's quite a contest. This month, it's "Avengers" star Mark Ruffalo. The Incredibly Hulky One went to a "No Kings" protest to complain about … rich folks and "White people." Now, while Ruffalo appears to represent both groups, he's also a true believer of lefty garbage. So, at least he's consistent. He told a lefty activist group, "We get to see who is really making our lives unbearable and making us so desperate. It's not the immigrants, it's the billionaires." Not the millionaires, just the folks with the "B." Why? Because Ruffalo has around $90 million himself, if Celebrity Networth is accurate. That's a lot closer to billionaire than me and most people reading this. Most of us just have the "air" part. 7. 'Tinfoil hat moment': Remember supposed comedian Kathy Griffin (she held the fake, bloody head of The Donald back in 2017) and former CNN host Don Lemon? Yeah, most people don't either. But they're still around and discussing 2024 election denial on "The Don Lemon Show" podcast, because it's OK when they do it. Griffin claimed, "I do not think he won in a free and fair election. How do you like that, lefties? Yeah, I said it. I'm Kathy Griffin, and I do not think Trump won in a free and fair election." Lemon was on her side in a tepid way, "You're not far off. I won't say that I disagree with you, but, you know, I'm an evidence person. I like to see the evidence." We could deny that Griffin is funny. At least we have evidence for that.